Skip to main content

Monoclonal Antibody Therapy

KRMC offers monoclonal antibody therapy to eligible patients for treatment of COVID-19. This therapy involves a one-time intravenous (IV) infusion of the antibodies. Early intervention with this therapy can shorten the duration of symptoms and reduce the risk of severe illness and hospitalization. 

Click Here to Schedule an Appointment Through Care Anywhere

See below for eligibility criteria:

You may be eligible for monoclonal antibody therapy if you are COVID-positive, within 10 days of symptom onset, and have any of the following risk factors:

  • A body mass index (BMI) ≥25
  • Chronic kidney disease
  • Diabetes
  • Liver disease or thalassemia 
  • Cardiovascular disease or hypertension
  • Immunosuppressive disease or treatment
  • Stroke or cerebrovascular disease
  • Substance use disorder
  • Sickle Cell disease
  • Current or former smoker
  • Chronic lung disease
  • 65 years of age and over
  • Neurodevelopmental disorder (ex. cerebral palsy) or other medically complex conditions 
  • Medical-related technological dependence (ex. tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19)
  • Genetic or metabolic syndromes and severe congenital anomalies
  • Other medical conditions or factors may qualify a patient for REGEN-COV therapy under the FDA's Emergency Use Authorization

Individuals who meet any of the following criteria are not eligible for monoclonal antibody therapy:

  • It has been more than ten days since symptom onset
  • Patients hospitalized due to COVID-19
  • Patients requiring new oxygen therapy or an increase in home oxygen therapy due to COVID-19I

If you have any questions (928) 681-8699. 

Learn more about the FDA's emergency use authorization of REGEN-COV monoclonal antibody therapy for treatment of COVID-19